Germany
· Delayed Price · Currency is EUR BioPorto Company Description
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally.
It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease.
The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays.
BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
| Country | Denmark |
| Founded | 1917 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 48 |
| CEO | Carsten Buhl |
Contact Details
Address: Tuborg Havnevej 15, st. Hellerup, 2900 Denmark | |
| Phone | 45 45 29 00 00 |
| Website | bioporto.com |
Stock Details
| Ticker Symbol | 2P4 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Carsten Buhl | Chief Executive Officer |
| Niels Nielsen | Chief Financial Officer |
| Hanne Sogaard | Head of Investor Relations |